Navigation Links
Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update
Date:2/23/2012

evenues of $10.2 million in the year ended December 31, 2010. The Company reported a net loss of $52.0 million, or a loss of $0.57 per basic and diluted share, for the year ended December 31, 2011, compared to a net loss of $61.6 million, or a loss of $0.87 per basic and diluted share for the year ended December 31, 2010. The $9.6 million reduction in net loss in 2011 was due primarily to $7.2 million of non-recurring severance and restructuring expenses in 2010.

2012 Financial Guidance At December 31, 2011, Idenix's cash and cash equivalents totaled $118.3 million. The Company expects that its current cash, cash equivalents and the anticipated royalty payments associated with product sales of Tyzeka®/Sebivo® (telbivudine) will be sufficient to sustain its operations through at least the next twelve months from December 31, 2011. This guidance assumes no milestone payments, license fees, reimbursement for development programs and no financing activities.

ABOUT IDENIXIdenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical Company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of patients with hepatitis C infection. For further information about Idenix, please refer to www.idenix.com.

CONFERENCE CALL AND WEBCAST INFORMATIONIdenix will hold a conference call today at 4:30 p.m. ET. To access the call, please dial (877) 640-9809 (U.S./Canada) or (914) 495-8528 (International) and enter passcode 48802750. A slide presentation will accompany the conference call and can be accessed on the Investor section of the Idenix website at www.idenix.com. Please log on approximately 10 minutes prior to the start of the call to ensure adequate time for any downloads that may be necessary.

A replay of the conference call and webcast will be
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
2. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
3. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
4. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
5. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
6. Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
7. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
8. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
9. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2009 Financial Results
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Idenix Announces Data Presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Ill., July 25, 2014 NOT FOR ... OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO ... OR REGULATIONS OF SUCH JURISDICTION AbbVie (NYSE: ABBV ... June 30, 2014. "This was another very ... per share above our original guidance and announced plans to ...
(Date:7/25/2014)... BOHEMIA, N.Y. , July 25, 2014 /PRNewswire-iReach/ -- Dr. ... Pediatrics clinic, GPM Pediatrics, reacts to a recent study, ... adulthood. Photo - http://photos.prnewswire.com/prnh/20140723/129709 ... mothers exposed to severe stress are more likely than others ... occurred months before pregnancy." There were two specific ...
(Date:7/24/2014)... 2014  Parnell Pharmaceuticals Holdings Ltd announces the ... added to Parnell,s already extensive pipeline through a ... biotechnology company. The compounds now known as PAR ... bone regeneration and dermal regeneration, respectively. Parnell has ... the veterinary market with the potential to also ...
Breaking Medicine Technology:AbbVie Reports Second-Quarter 2014 Financial Results 2AbbVie Reports Second-Quarter 2014 Financial Results 3AbbVie Reports Second-Quarter 2014 Financial Results 4AbbVie Reports Second-Quarter 2014 Financial Results 5AbbVie Reports Second-Quarter 2014 Financial Results 6AbbVie Reports Second-Quarter 2014 Financial Results 7AbbVie Reports Second-Quarter 2014 Financial Results 8AbbVie Reports Second-Quarter 2014 Financial Results 9AbbVie Reports Second-Quarter 2014 Financial Results 10AbbVie Reports Second-Quarter 2014 Financial Results 11AbbVie Reports Second-Quarter 2014 Financial Results 12AbbVie Reports Second-Quarter 2014 Financial Results 13AbbVie Reports Second-Quarter 2014 Financial Results 14AbbVie Reports Second-Quarter 2014 Financial Results 15AbbVie Reports Second-Quarter 2014 Financial Results 16AbbVie Reports Second-Quarter 2014 Financial Results 17AbbVie Reports Second-Quarter 2014 Financial Results 18AbbVie Reports Second-Quarter 2014 Financial Results 19AbbVie Reports Second-Quarter 2014 Financial Results 20AbbVie Reports Second-Quarter 2014 Financial Results 21AbbVie Reports Second-Quarter 2014 Financial Results 22AbbVie Reports Second-Quarter 2014 Financial Results 23AbbVie Reports Second-Quarter 2014 Financial Results 24AbbVie Reports Second-Quarter 2014 Financial Results 25AbbVie Reports Second-Quarter 2014 Financial Results 26AbbVie Reports Second-Quarter 2014 Financial Results 27AbbVie Reports Second-Quarter 2014 Financial Results 28AbbVie Reports Second-Quarter 2014 Financial Results 29AbbVie Reports Second-Quarter 2014 Financial Results 30AbbVie Reports Second-Quarter 2014 Financial Results 31AbbVie Reports Second-Quarter 2014 Financial Results 32AbbVie Reports Second-Quarter 2014 Financial Results 33AbbVie Reports Second-Quarter 2014 Financial Results 34AbbVie Reports Second-Quarter 2014 Financial Results 35AbbVie Reports Second-Quarter 2014 Financial Results 36
... , WOONSOCKET, R.I., Oct. 15 CVS/pharmacy announced today ... October 22, in light of manufacturer delays in delivery ... However, MinuteClinic will continue to administer seasonal flu ... the flu season with the supply of vaccine replenished ...
... Cynosure, Inc. (Nasdaq: CYNO ... of light-based aesthetic treatment systems, today announced that the company ... 27, 2009 at 9:00 a.m. ET. , On the call, ... President and Chief Financial Officer Timothy Baker will discuss Cynosure,s ...
Cached Medicine Technology:CVS Caremark Announces Updates to Flu Vaccine Program 2CVS Caremark Announces Updates to Flu Vaccine Program 3Cynosure to Announce Third-Quarter 2009 Financial Results on October 27 2
(Date:7/26/2014)... Wa (PRWEB) July 26, 2014 ... review recently updated by Vkool.com, this is ... and safe methods for treating all types ... including:,     Tinnitus due to ... tinnitus ,     Nerve pathway tinnitus , ...
(Date:7/26/2014)... (PRWEB) July 26, 2014 The U.S. Food ... list that includes a new medication guide for AndroGel to ... serious side-effect of taking the topical low testosterone medication, notes ... AbbVie Inc., the makers of the low testosterone theapy drug, ... of pain, swelling or redness as signs of a blood ...
(Date:7/26/2014)... According to the "Get Rid Tattoo Naturally" ... comprehensive guide that provides readers with safe and natural ... also teaches them how to fade dark colored tattoos, ... own home for drastic results. , Vkool reveals ... includes step-by-step tutorials and product recommendations for treating different ...
(Date:7/25/2014)... 2014 2014 Deep Research ... Chromatography Industry” is a professional and in-depth ... Gel Permeation Chromatography market. The report provides ... Permeation Chromatography definition, classification, application, and industry ... This research covers the international market analysis, ...
(Date:7/25/2014)... A federal judge has denied defense ... Pinnacle hip lawsuits ( http://www.depuypinnacle-lawsuit.com/ ) selected as ... go before a jury on September 1, 2014, Bernstein ... 18th, U.S. District Judge Ed Kinkeade of the Northern ... may proceed to trial against Johnson & Johnson, the ...
Breaking Medicine News(10 mins):Health News:Tinnitus Miracle Book Review Exposes Thomas Coleman's Guide for Treating Tinnitus – Vkool.com 2Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 2Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 3Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 4Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 5Health News:"Get Rid Tattoo Naturally" Book Review Exposes Jason Carter's Tattoo Removal Guide – Vkool.com 2Health News:"Get Rid Tattoo Naturally" Book Review Exposes Jason Carter's Tattoo Removal Guide – Vkool.com 3Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 2Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 2Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 4
... in brain development that underlie autism spectrum disorder (ASD) ... months, according to research reported online today in the ... associated with ASD (impaired social communication and repetitive behaviors) ... researchers found clear differences in brain communication pathways as ...
... the initial steps that occur in the body when type ... adult. The analysis comes from a team of researchers ... have expertise both in the laboratory and in treating patients. ... 48 hours of their diagnosis with type 1 diabetes, an ...
... -- When it comes to helping Parkinson,s disease patients ... effective than stretching or balance exercises, a new study ... plays an important part in the treatment of Parkinson,s ... director of the Movement Disorder Program at Winthrop-University ...
... DETROIT Ovarian cancer, which killed 15,000 American women ... cancer. A team of Wayne State University School of ... rates in ovarian cancer patients. The "freeze and ... cancerous tumors, said Peter Littrup, M.D., professor of radiology ...
... HealthDay Reporter , THURSDAY, Feb. 16 (HealthDay News) -- ... heart failure, experts say new treatments have dramatically improved ... patients. "The present environment for heart failure is ... truly remove the term ,failure, from the description of ...
... A mixture of current drugs and carbon nanoparticles shows ... combined with radiation therapy, according to new research by ... Cancer Center. The work blazes a path for ... individual patients. The therapy uses carbon nanoparticles to encapsulate ...
Cached Medicine News:Health News:Researchers see differences in Autism brain development as early as 6 months 2Health News:As diabetes emerges, researchers track disease's first steps 2Health News:As diabetes emerges, researchers track disease's first steps 3Health News:As diabetes emerges, researchers track disease's first steps 4Health News:Weight Training May Help Parkinson's Patients Retain Function 2Health News:Wayne State proves targeted tumor freezing therapy increases ovarian cancer survival 2Health News:Treatment Advances Improve the Odds for Heart Failure Patients 2Health News:Treatment Advances Improve the Odds for Heart Failure Patients 3Health News:Nanoparticles may enhance cancer therapy 2Health News:Nanoparticles may enhance cancer therapy 3Health News:Nanoparticles may enhance cancer therapy 4
... applier consists of an applier shaft with attached ... titanium clips. , ,The clip applier jaw ... structure. As the handles of the applier are ... vessel or structure. As the handles are released, ...
... Utilizing a disposable loading unit, the LDS-2™ instrument ... tissue within the cartridge jaw and the knife ... clips. The instrument is activated by squeezing the ... go. The size of the clip is determined ...
... LIGACLIP Clip Applier is a reusable instrument ... clips. This instrument is used with LIGACLIP ... either 316L stainless steel or titanium. The ... tubular structures where a nonabsorbable ligating device ...
SM&trade Single Use Loading Unit with 35 staples available in regular and wide sizes....
Medicine Products: